Tag:
Boston Scientific
Latest Headlines
Latest Headlines
Boston Sci touts long-term safety of Promus stent, despite FDA warning
Boston Scientific unveiled the results of a two-year safety study on its Promus Element drug-eluting stents, boasting of "excellent" results for the device.
Boston Sci, Abbott gain European sign-off for stent products & services
With European regulatory approvals in hand, Boston Scientific (BSX) and Abbott ($ABT) are both debuting stents or stent-related treatment offerings overseas that illustrate how rigorous competition in the space continues to be.
Boston Sci boasts stroke risk reduction for Watchman implant
Boston Scientific's Watchman device was found to reduce stroke risk in patients who can't take oral anticoagulants, a development that could help push the device toward U.S. availability.
Biotronik wins FDA approval for next-gen ICD and CRT-D
The competition to gain market share with next-generation ICD and CRT-Ds just got tougher. German device giant Biotronik won FDA regulatory approval for its new Lumax 740 implantable cardioverter defibrillators and cardiac resynchronization therapy devices.
Boston Scientific's CEO: CRM business in active rebuilding mode
Boston Scientific's launch of new pacemaker products and a pending acquisition will be crucial toward reversing the company's declines in cardiac rhythm management revenue as well as pushing ahead with global expansion, CEO Hank Kucheman says.
Boston Scientific gains FDA sign-off for 3 new pacemakers
Boston Scientific ($BSX) is touting a slew of new FDA approvals. Regulators signed off on the Natick, MA-based company's Ingenio and Advantio pacemakers and also its Invive cardiac resynchronization therapy pacemakers.
FDA panel gives Cameron Health good news on implantable ICD
Good news for Cameron Health (and Boston Scientific ($BSX)). An FDA panel voted Thursday 7-1 to recommend approval of the company's implantable defibrillator.
Boston Sci heralds Emerge launch in Europe, eyes U.S., other markets
Coming off the news of its defibrillator issues, Boston Scientific ($BSX) had some good news this morning. The devicemaker has received CE mark approval and witnessed the European market launch of the Emerge PTCA dilatation catheter.
Boston Sci heart device malfunction led to patient death
Boston Scientific ($BSX) is experiencing its own problems after the relevation of a flaw in its Cognis and Teligen defibrillators.
Boston Sci sees earnings jump as sales slip
Boston Scientific's ($BSX) Q1 earnings numbers dazzled Thursday as it reported net income of $113 million, or $0.08 per share--a big jump from $46 million, or $0.03 per share, during the same period last year.
